- Home
- PETS vs SCYX Comparison
PETS vs SCYX Comparison
Compare PETS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETS
- SCYX
- Stock Information
- Founded
- PETS 1996
- SCYX 1999
- Country
- PETS United States
- SCYX United States
- Employees
- PETS N/A
- SCYX N/A
- Industry
- PETS Retail-Drug Stores and Proprietary Stores
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- PETS Consumer Staples
- SCYX Health Care
- Exchange
- PETS Nasdaq
- SCYX Nasdaq
- Market Cap
- PETS 82.0M
- SCYX 76.7M
- IPO Year
- PETS N/A
- SCYX 2014
- Fundamental
- Price
- PETS $3.98
- SCYX $1.46
- Analyst Decision
- PETS Sell
- SCYX Buy
- Analyst Count
- PETS 2
- SCYX 1
- Target Price
- PETS $3.50
- SCYX N/A
- AVG Volume (30 Days)
- PETS 174.8K
- SCYX 102.9K
- Earning Date
- PETS 10-28-2024
- SCYX 11-11-2024
- Dividend Yield
- PETS 28.95%
- SCYX N/A
- EPS Growth
- PETS N/A
- SCYX N/A
- EPS
- PETS N/A
- SCYX N/A
- Revenue
- PETS $270,772,000.00
- SCYX $9,666,000.00
- Revenue This Year
- PETS N/A
- SCYX N/A
- Revenue Next Year
- PETS $3.27
- SCYX $126.72
- P/E Ratio
- PETS N/A
- SCYX N/A
- Revenue Growth
- PETS 2.26
- SCYX N/A
- 52 Week Low
- PETS $2.90
- SCYX $1.26
- 52 Week High
- PETS $10.53
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- PETS 54.93
- SCYX 48.24
- Support Level
- PETS $3.89
- SCYX $1.47
- Resistance Level
- PETS $4.22
- SCYX $1.62
- Average True Range (ATR)
- PETS 0.20
- SCYX 0.07
- MACD
- PETS -0.02
- SCYX 0.01
- Stochastic Oscillator
- PETS 47.37
- SCYX 44.14
About PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.